NCT02151643View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

May 7, 2014

Primary Completion Date

March 18, 2015

Study Completion Date

March 18, 2015

Conditions
Hyperphosphataemia
Interventions
DRUG

PT20

Modified ferric oxide adipate tablets

DRUG

Placebo

Placebo tablets matched to each PT20 dose arm

Sponsors

Collaborators (1)

Clinipace Worldwide
All Listed Sponsors
collaborator

Clinipace Worldwide

INDUSTRY

lead

Phosphate Therapeutics

INDUSTRY